FENC

Fennec Pharmaceuticals Inc. (FENC) - Q3 2024 10-Q Summary

Business Context and Reporting Period

Fennec Pharmaceuticals Inc. is a commercial-stage specialty pharmaceutical company focused on its sole product, PEDMARK (sodium thiosulfate injection), approved by the FDA to reduce ototoxicity in pediatric patients receiving cisplatin. The company also markets the product as PEDMARQSI in Europe. This report covers the quarterly period ended September 30, 2024.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Surge (YTD): Total revenue increased by $28.1 million year-over-year for the nine-month period, driven primarily by a one-time $17.96 million licensing revenue recognition from the Norgine Pharma agreement in Q1 2024. Product sales grew 88% YTD to $21.66 million.
• Profitability Shift: The company reported a net income of $1.55 million for the nine months ended September 30, 2024, compared to a net loss of $13.36 million in the same period in 2023. However, Q3 2024 standalone results returned to a net loss of $5.74 million due to higher operating expenses.
• Expense Growth: Operating expenses increased significantly. Selling and marketing expenses rose 36% in Q3 and 75% YTD, attributed to expanded outreach to community oncology centers. General and administrative expenses increased 61% in Q3 and 39% YTD, driven by litigation costs and professional fees related to the Norgine transaction.
• Liquidity Improvement: Cash and cash equivalents increased from $13.27 million at year-end 2023 to $40.32 million at September 30, 2024, fueled by the Norgine upfront payment and positive operating cash flows of $28.45 million YTD.

Outlook, Risks, and Unusual Items

• Norgine Licensing Deal: In March 2024, Fennec entered an exclusive license with Norgine to commercialize PEDMARQSI in Europe, Australia, and New Zealand. The deal included a ~$43.2 million upfront payment (recognized partially as revenue) and potential milestones up to ~$230 million. Norgine is preparing for an EU launch.
• Intellectual Property Litigation: The company is engaged in ongoing patent infringement litigation against CIPLA regarding generic versions of PEDMARK. Fennec holds six patents listed in the FDA Orange Book, with expiration dates in 2039, and relies on Orphan Drug Exclusivity until September 2029.
• Internal Control Material Weakness: Management identified a material weakness in internal controls over financial reporting related to the measurement and classification of fees and allowances paid to distributors for distinct services under ASC 606. Remediation plans are underway.
• Debt Obligations: The company has a senior secured convertible note facility with Petrichor Opportunities Fund I LP. As of September 30, 2024, $30 million in principal is outstanding, with an interest rate of Prime + 4.5% (13% at period end) plus 3.5% PIK interest (which ceased accruing in August 2024).
• Executive Appointments: In October 2024, the company appointed a new Chief Medical Officer, Chief Commercial Officer, and Chief Strategy Officer to support commercialization efforts.

Investor Verification Checklist

• Revenue Sustainability: Verify the trajectory of product sales excluding the one-time Norgine licensing revenue to assess organic growth.
• Internal Control Remediation: Monitor the progress of fixing the material weakness regarding distributor fees and allowances to ensure future financial reporting reliability.
• Patent Litigation Status: Track the outcome of the CIPLA litigation, as a loss could impact market exclusivity beyond the Orphan Drug period.
• Cash Burn Rate: Assess the runway provided by the $40.3 million cash balance against the elevated operating expenses (particularly G&A and S&M) in the absence of further large licensing deals.
• Debt Conversion Risk: Review the terms of the convertible notes ($7.89 conversion price) relative to the current stock price to evaluate potential dilution.